Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02798861 · ClinicalTrials.gov registry record
Controlled Attenuation Parameter (CAP) in Liver Allografts
A clinical trial, sponsored by Andres Duarte-Rojo.
- Completed
- Registry status
- 160
- Enrollment target
NCT02798861: Completed study, sponsored by Andres Duarte-Rojo.
NCT02798861 is a clinical trial that has completed, run by Andres Duarte-Rojo. The registered enrollment target is 160 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02798861 has completed, sponsored by Andres Duarte-Rojo.
- COMPLETED
- Registry status
- 160 participants
- Enrollment target
Study Summary
The primary aim is to determine the accuracy of CAP in the quantification of liver steatosis using liver biopsies as reference. Secondarily, investigators will correlate transient elastography (TE) and CAP results, analyze possible associations between CAP/TE and post-liver transplant (LT) clinical outcomes, and evaluate the change in CAP after LT. The study aims to include as many donors as needed to achieve at least 120 transplanted liver allografts.
Primary Outcome
CAP accuracy in quantification of liver steatosis to be determined using liver biopsies as reference
Interventions
- DEVICE Fibroscan 402/530
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2016-09-07 |
| Est. Completion | 2019-06-01 |
What the finished NCT02798861 record still lists
NCT02798861 is an observational study that tracks outcomes without assigning an intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Fibroscan 402/530 is the first listed.
NCT02798861 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02798861 about?
NCT02798861 is a clinical study titled "Controlled Attenuation Parameter (CAP) in Liver Allografts". The primary aim is to determine the accuracy of CAP in the quantification of liver steatosis using liver biopsies as reference. Secondarily, investigators will correlate transient elastography (TE) and CAP results, analyze possible associations between CAP/TE and post-liver transplant (LT) clinical ...
What is the current status of trial NCT02798861?
This trial is currently completed. The enrollment target is 160 participants. The study started on 2016-09-07. Estimated completion is 2019-06-01.
What interventions are being tested in trial NCT02798861?
The interventions under investigation include: Fibroscan 402/530 (DEVICE).
Who is sponsoring clinical trial NCT02798861?
This trial is sponsored by Andres Duarte-Rojo, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI